NasdaqGM:SMMTBiotechs
A Look At Summit Therapeutics (SMMT) Valuation After FDA Acceptance Of Ivonescimab BLA
Summit Therapeutics (SMMT) just cleared a key regulatory hurdle, with the FDA accepting its Biologics License Application for ivonescimab plus chemotherapy in EGFR mutated non squamous NSCLC after tyrosine kinase inhibitor therapy.
See our latest analysis for Summit Therapeutics.
Alongside the FDA accepting the BLA for ivonescimab, Summit Therapeutics’ recent 7 day share price return of 5.8% contrasts with a 30 day share price decline of 10.5%. At the same time, the 3 year total shareholder...